Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P16885
UPID:
PLCG2_HUMAN
Alternative names:
Phosphoinositide phospholipase C-gamma-2; Phospholipase C-IV; Phospholipase C-gamma-2
Alternative UPACC:
P16885; D3DUL3; Q3ZTS2; Q59H45; Q969T5
Background:
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2, also known as Phosphoinositide phospholipase C-gamma-2, plays a pivotal role in transmembrane signaling by generating diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). These second messenger molecules are crucial for various cellular processes.
Therapeutic significance:
This protein's involvement in Familial cold autoinflammatory syndrome 3 and Autoinflammation, antibody deficiency, and immune dysregulation highlights its potential as a target for therapeutic intervention. Understanding its role could lead to novel treatments for these immune disorders.